We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Seattle Genetics Nabs Another Approved Indication for Cancer Drug Adcetris
Seattle Genetics Nabs Another Approved Indication for Cancer Drug Adcetris
Seattle Genetics has received FDA approval for its cancer drug Adcetris to treat patients with Hodgkin lymphoma who are at high risk of relapse following an autologous haematopoietic stem cell transplant to help curb the disease’s progression.